Prangenix

Partners & Collaborations

At Prangenix Therapeutics, we don’t believe in working alone—because solving the world’s hardest health challenges takes more than one breakthrough. It takes a movement. A collective of changemakers—scientists, doctors, hospitals, and entrepreneurs—united by a shared mission: to bring clarity to cancer care and rewrite what’s possible in regenerative medicine.

Collaborations

Types of Collaborations We Provide

We’re actively forging partnerships across academia, clinical networks, and the biotech industry to co-develop, co-validate, and co-innovate solutions that make a real difference—starting from Eastern Uttar Pradesh and expanding outwards.

Academic Collaborations

Academic Collaborations

Partnering with universities, biotech incubators, and research labs to translate early-stage discoveries into clinical applications.

  • Biomarker panel development
  • Epigenetic assay optimization
  • qCSC dynamics
  • CRISPR-based design
Clinical Partnerships

Clinical Partnerships

Building a network of 50+ hospitals, cancer centers, and diagnostic labs to validate and deploy our non-invasive testing solutions at scale.

  • Real-world sample collection
  • Liquid biopsy validation
  • MRD monitoring
  • Early detection access
Industry Collaborations

Industry Collaborations

Partnering with biotech, pharma, and AI health-tech firms to co-create next-gen diagnostics and therapies for better healthcare.

  • Liquid biopsy platforms
  • Genomics AI tools
  • Regenerative stem cell therapy
  • CRISPR/CAR-T pipeline
Why Collab With Us

Why Collaborate with Prangenix

At Prangenix Therapeutics, we bridge the gap between vision and validation. Whether you're a researcher, clinician, biotech innovator, or healthcare partner, we provide the expertise, resources, and ecosystem to turn innovative ideas into impactful solutions.

Accelerate Innovation

Transform untested ideas into validated solutions using cutting-edge technologies, clinical frameworks, and translational expertise for impactful healthcare advancements.

Scientific Collaboration

Partner with our experts to integrate deep molecular insights, strengthening research pipelines and accelerating precision diagnostics and therapeutic discoveries.

Real-World Validation

Leverage patient samples, clinical data, and diagnostic testing to ensure evidence-backed outcomes and improved treatment decision-making capabilities.

Healthcare Launchpad

Access India’s rapidly evolving healthcare ecosystem, unlocking faster integration, scalability, and growth opportunities for innovative solutions.

The Science of Progress is Partnership

At Prangenix, we believe collaboration is not just a strategy—it’s a catalyst. Every breakthrough we imagine, every diagnostic we deliver, and every therapy we design is made stronger through the power of shared vision. Whether you’re a researcher decoding the unknown, a clinician on the frontlines of care, or a startup rewriting the rules of biology—we invite you to build with us. Because when we collaborate, we don’t just advance science—we accelerate hope. Let’s co-create a future where precision medicine is not a privilege, but a promise fulfilled for all.

Ready to collaborate?

Tell us about your idea, capability or interest and we’ll get back to you to explore fit and next steps.

FAQ

Frequently Asked Questions

1. What diagnostic services does Prangenix provide?
We offer modular liquid and tissue diagnostics, custom biomarker panels, single-cell profiling, and personalized therapy reports—all tailored to oncology and chronic disease care.
2. What is a modular diagnostic panel?
Modular panels allow clinicians to choose specific genes or biomarkers (5–10 targets) for testing—customized to each patient’s needs—rather than using fixed panels.
3. Are your diagnostics suitable for head and neck cancers?
Yes. We specialize in head and neck oncology with high-sensitivity tests designed to detect key mutations, fusion genes, and epigenetic markers.
4. Can I use your services for cardiovascular or immune-related diseases?
Yes. While our core focus is cancer diagnostics, we are developing panels for cardiovascular (CardioX) and immune system profiling (ImmunoX).
5. What is your dual-track innovation model?
We offer Track 1 for liquid biopsy-based early cancer detection, and Track 2 for single-cell profiling of cancer stem cells (qCSCs) to guide therapeutic decisions and future drug design.
5. What is rare-cell profiling, and why is it important?
Rare-cell profiling isolates and analyzes cancer stem cells (qCSCs) and circulating tumor cells (CTCs)—critical for understanding relapse and drug resistance.
6. What is CellCapture™ and Single-Cell Discover™?
These are our proprietary platforms for isolating rare cells and performing high-throughput single-cell RNA sequencing to guide therapeutic strategies.
7. How are therapy blueprints generated?
Using scRNA-seq data and AI, we create therapy blueprints that guide treatment by identifying druggable targets and resistance patterns.
8. Can hospitals integrate your reports into their systems?
Yes. All results are EMR and LIMS compatible, delivered through interactive dashboards designed for seamless clinical integration.
9. Do you offer beta access to your new services?
Yes. We welcome hospitals, labs, and researchers to partner with us in testing and validating our upcoming diagnostics and therapeutic tools.
10. Who can benefit from your services?
Oncologists, hospitals, researchers, pharma companies, and patients seeking early detection, treatment monitoring, and precision therapy planning.